

# **COVID-19 Vaccine Provider Update**

September 8, 2021

# Summary Points:

- ▶ All Covid vaccine orders will be filled by M & D at this time until Mckesson/Pfizer resumes shipments into Louisiana
- ▶ There is a delay in receiving orders from the time order is placed to delivery. We are working to fill all orders and catch up.
- ▶ If you had a vaccine loss of Covid Vaccine due to Hurricane Ida please fill out the Vaccine Loss Report Form. You can retrieve this form from your Regional Immunization Consultant. Their information can be found on the LINKS homepage.

## Summary (cont.)

- ▶ On August 14, CDC recommended that people who are moderately to severely immunocompromised, and are fully vaccinated with an mRNA COVID-19 vaccine, receive an additional dose of that same mRNA COVID-19 vaccine
- ▶ • Those seeking vaccination fill out the state's self-attestation form.
- ▶ • CDC recommends the additional dose of an mRNA COVID-19 vaccine be administered at least four weeks after a second dose of Pfizer or Moderna COVID-19 vaccine
- ▶ • If the mRNA vaccine product given for the first two doses is not available or is unknown, either mRNA COVID-19 vaccine product may be administered
- ▶ • The recommendation for additional doses does not apply to those who received the J&J vaccine

## Summary (Cont.)

- ▶ An “**additional dose**” refers to an extra dose needed because initial vaccine series did not produce an adequate immune response in those previously vaccinated immunocompromised individuals
- ▶ A “**booster dose**” beyond the initial series completion refers to an extra dose needed because initial vaccine series protection has waned over time
- ▶ CDC has asked state’s to prepare for general public third booster doses, with a possible start date of September 20. (mRNA vaccines only). The indication is that the general public would be eligible for a third booster of mRNA vaccine at 8 months. (this has not been approved by CDC, this is an initial timeframe that was mentioned for planning purposes)

## Summary (Cont.)

- ▶ CDC has approved the six months to nine months expiration date extension for Pfizer doses in Louisiana. This six to nine months expiration extension will result in approximately 60,000 M&D Pfizer doses being made available to fill new provider orders. Due to the large volume and CDC's first in/first out distribution policy, high volume single orders placed in LINKS that normally come directly from the manufacturer will temporarily come from M&D. Lower volume orders of Pfizer will continue to be filled and delivered by Morris & Dickson, as usual. M&D will begin redistributing Pfizer vaccine with the updated expiration dates detailed below, until all of these doses with extended dates have been ordered:
- ▶ Lot Number (EP6955): **New Expiration Date: 9/30/2021**
- ▶ Lot Numbers (EN6207, ER8734, EW0150, ER8729, EW0158, ER8727, EW0162, ER8733 ): **New Expiration Date: 10/31/2021**


## Summary (Cont.)

- ▶ M & D now making vaccine deliveries to all regions, except regions 1 and 3. As has been their procedure from the start of the vaccination response, all sites expecting a delivery are contacted the day before the delivery, to ensure site staff will be available at time of delivery and confirm that sites have proper storage space ready to store vaccines at appropriate temperatures. Those sites in storm-impacted areas that are unable to receive the delivery due to power issues, etc., will receive their delivery once they can verify they are ready to properly store their order/shipment.
- ▶ Licensed LTCFs (Nursing Homes, Adult Residential Care, and Intermediate Care for DD) had until Friday, 8/27, to notify LDH of their onsite third mRNA vaccine dose vaccination plans for their staff and residents. LIPA will work/follow-up with non-responders to secure a pharmacy provider that will provide the vaccinations onsite, once the recommendation for third booster is provided by CDC.

## Summary (Cont.)

- ▶ Administration of booster shots is not yet recommended by the FDA or CDC.
- ▶ Administration of the product off label may not be covered under the PREP Act or the PREP Act declaration; therefore, providers may not have immunity from claims.
- ▶ Individuals who receive an off-label dose may not be eligible for compensation under the Countermeasures Injury Compensation Program after a possible adverse event.
- ▶ CDC has defined the scope of the CDC COVID-19 Vaccination Program in terms of how the USG-provided vaccines may be used in the program. Providers giving off-label doses would be in violation of the CDC Program provider agreement potentially impacting their ability to remain a provider in the CDC program.
- ▶ Booster shot administration fees may not be reimbursable by payers.

# COVID-19 cases (9/7/2021)





# Vaccine Administrations as of 9/7/21

Initiated series: 2,325,443 (50% of population) up from 44.8% last meeting

- 59.3% of people aged 12+ up from 53.1% last meeting
- 61.8% of people aged 18+ up from 55.9% last meeting
- 85.8% of people aged 65+ up from 82.6% last meeting

Completed series: 1,966,214 (42.3% of population) up from 37.6% last meeting



- 50.1% of people aged 12+ up from 44.5% last meeting
- 52.8% of people aged 18+ up from 47.6% last meeting
- 80.7% of people aged 65+ up from 77.4% last meeting

Total doses administered: 4,266,101 +482,636 since last meeting


Total doses delivered: 5,417,300 +817,920 since last meeting

% of delivered that has been administered: 78.7% down from 82.3% last meeting


# Doses Administered (9/7/2021)



# Vaccinations by Week




# % of population completing series by Region (9/7/2021)




Source: [ldh.la.gov/coronavirus](https://ldh.la.gov/coronavirus)


# Series Completed by Age



# Vaccination Status by Age



# LA Ranking as of 9/7/2021



Percent of population with at least one dose

LA ranks 45 of 50 (moved up 2 spots from last month)

Florida: 64.4%

Texas: 57.6%

Alabama: 50.5%

**Louisiana: 50.0%**

North Dakota: 48.8%


Mississippi: 47.7%

West Virginia: 47.3%

Wyoming: 45.9%

Idaho: 44.7%

**US average: 62.3%**



Percent of population who has completed series

LA ranks 43 of 50 (moved up 3 spots from last month)

Florida: 53.8%

Texas: 48.1%

**Louisiana: 42.3%**

North Dakota: 42.1%

Georgia: 42.1%

West Virginia: 39.8%

Mississippi: 39.6%

Idaho: 39.5%

Wyoming: 39.3%

Alabama: 39.1%

**US average: 53.0%**

# Booster Doses for Immunocompromised

- ▶ As of Saturday, Aug 14, individuals with conditions causing moderate or severe immunosuppression are recommended and able to receive a 3<sup>rd</sup> “supplemental” dose of mRNA vaccine 28 days or longer after receiving their 2<sup>nd</sup> dose.
  - ▶ Qualifying conditions include:
    - ▶ Active cancer treatment for tumors or cancers of the blood
    - ▶ Received an organ transplant and are taking medicine to suppress the immune system
    - ▶ Stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
    - ▶ Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
    - ▶ Advanced or untreated HIV infection
    - ▶ Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response
    - ▶ Other conditions which cause moderate or severe immunosuppression similar to the above conditions
  - ▶ Patients may self-attest to these conditions

# Vaccine breakthrough data, Louisiana


- ▶ Those not fully vaccinated account for 89% of new cases August 5-11
  - ▶ 14,650 total vaccine breakthrough infections, + 4711 since last week
- ▶ Those not fully vaccinated account for 91% of COVID hospitalizations on 8/17
- ▶ Those not fully vaccinated account for 80% of deaths reported August 5-11
  - ▶ 162 total reported deaths among fully vaccinated individuals who are COVID+, +62 since last week
- ▶ Among breakthrough cases with severe outcomes:
  - ▶ Age range: 20-98, median 74
  - ▶ 50% female, 50% male
  - ▶ 65% White, 31% Black, 2% other, 2% unknown
- ▶ Underlying conditions among breakthrough deaths:

Diabetes	46%
CKD	31%
Chronic Liver Disease	3%
Autoimmune Disease	10%
Immunosuppressed	15%
On Immunosuppressants	12%
No underlying conditions	25%



# Severe Adverse Event Surveillance

- ▶ Severe adverse event case definition:
  - ▶ Anaphylaxis requiring hospitalization within 3 hours of vaccination, OR
  - ▶ Death within 24 hours of vaccination without an alternative cause, OR
  - ▶ Other serious and life-threatening adverse event requiring hospitalization within 3 days of vaccination with no alternative cause, OR
  - ▶ Both acute thrombosis **AND** new onset thrombocytopenia (platelet count  $<150,000/\mu\text{L}$ ) requiring hospitalization with onset within 6 weeks following vaccination.
  - ▶ Myocarditis/pericarditis requiring hospitalization within 2 weeks of vaccination with no alternative cause
- ▶ Total number of reported events resulting in hospitalization/death that were investigated: 97 (no new investigations)
- ▶ **Current LA severe adverse events meeting case definition: 8**
  - ▶ 1 anaphylaxis, 5 other, 2 myocarditis (no deaths)

SLEEVES UP  
BRING BACK  
  
LOUISIANA

June 11, 2021

# PROVIDER RESOURCES

---

## COVID-19 VACCINE INFORMATION WEBPAGE

<https://ldh.la.gov/index.cfm/page/3880>

- COVID-19 Vaccine Provider Toolkit
- COVID-19 Vaccine Storage & Handling
- Common COVID-19 Vaccine Questions for Providers
- Information and Toolkit for Pediatricians
- COVID-19 Provider Training Material
- Newsletter and Important Documents





*Get Vaccinated*  
**GET IN FREE!**



BRING BACK  LOUISIANA